• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Trump drug pricing tweet sends pharma stocks down

March 7, 2017 By Sarah Faulkner

Trump drug pricing tweet sends pharma stocks downShares in Pfizer (NYSE:PFE), Merck (NYSE:MRK) and Amgen (NSDQ:AMGN) fell slightly this morning after President Donald Trump tweeted that he was working on a “new system” to lower drug prices.

“I am working on a new system where there will be competition in the Drug Industry,” he wrote. “Pricing for the American people will come way down!”

PFE and MRK shares were trading down 1.1% this morning, while AMGN shares dropped 1.4%.

This is not the new administration’s 1st attack on the industry’s drug pricing strategies. In January, he said that pharmaceutical companies were “getting away with murder” with what they charge the government for drugs.

“We’re the largest buyer of drugs in the world, and yet we don’t bid properly,” he said at his 1st press conference. “We’re going to start bidding, and we’re going to save billions of dollars over a period of time.”

In his 1st address to Congress, Trump said more should be done to bring down “artificially high” drug prices and called for speeding up drug approvals within the FDA.

A January meeting with executives from pharmaceutical companies including Johnson & Johnson (NYSE:JNJ), Amgen, Merck and Eli Lilly (NYSE:LLY) seemed to signal a defusing of tensions.

During the meeting, Amgen CEO Robert Bradway reportedly committed to adding 1,600 U.S. jobs at his biotech.

Eli Lilly and Merck told Reuters that they were encouraged by the President’s focus on innovation and that the meeting also touched upon issues like negotiating stronger trade agreements, tax reform and getting rid of outdated regulations.

Yesterday, a group of senators requested pricing information from Marathon Pharmaceuticals for its $89,000 muscular dystrophy drug.

“The circumstances surrounding the development of Emflaza, and the benefits that will accrue to Marathon as a result of its approval of the drug, raise serious questions about whether there is any justification for such a dramatically high price,” the senators wrote.

Material from Reuters was used in this report.

Filed Under: Featured, Pharmaceuticals, Wall Street Beat Tagged With: Amgen, Eli Lilly & Co., johnsonandjohnson, Marathon Pharmaceuticals, Merck, Pfizer Inc.

IN CASE YOU MISSED IT

  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS